iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Biocon Biologics secures 3-year contract from Ministry of Health Malaysia

29 Apr 2022 , 01:33 AM

Biocon Biologics a subsidiary of Biocon announced that its subsidiary Biocon Sdn Bhd in Malaysia has been awarded a three-year contract valued at USD 90 million for its recombinant human insulin brand Insugen by the Ministry of Health Malaysia Biocon Sdn Bhd will manufacture and supply its range of insulins to its partners Duopharma Marketing Sdn Bhd a subsidiary of Duopharma Biotech a leading pharmaceutical and biotech company in Malaysia Biocon Biologics Insugen formulations will be available to patients at all Ministry of Health hospitals district health offices and health clinics

Related Tags

  • Announcements
  • BSE
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.